GABRIEL
ZUBILLAGA GARMENDIA
Investigador/a en el periodo 1990-2016
Hospital Universitari de Bellvitge
l'Hospitalet de Llobregat, EspañaPublicaciones en colaboración con investigadoras/es de Hospital Universitari de Bellvitge (3)
2016
-
Factors associated with fatality during the intensive phase of anti-tuberculosis treatment
PLoS ONE, Vol. 11, Núm. 8
2006
-
Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae
Journal of Antimicrobial Chemotherapy, Vol. 57, Núm. 3, pp. 536-545
2003
-
Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults
Journal of Antimicrobial Chemotherapy, Vol. 52, Núm. 5, pp. 826-836